Collegium Pharmaceutical Net Worth
Collegium Pharmaceutical Net Worth Breakdown | COLL |
Collegium Pharmaceutical Net Worth Analysis
Collegium Pharmaceutical's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Collegium Pharmaceutical's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Collegium Pharmaceutical's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Collegium Pharmaceutical's net worth analysis. One common approach is to calculate Collegium Pharmaceutical's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Collegium Pharmaceutical's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Collegium Pharmaceutical's net worth. This approach calculates the present value of Collegium Pharmaceutical's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Collegium Pharmaceutical's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Collegium Pharmaceutical's net worth. This involves comparing Collegium Pharmaceutical's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Collegium Pharmaceutical's net worth relative to its peers.
To determine if Collegium Pharmaceutical is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Collegium Pharmaceutical's net worth research are outlined below:
| Collegium Pharmaceutical generated a negative expected return over the last 90 days | |
| Collegium Pharmaceutical currently holds 674.28 M in liabilities with Debt to Equity (D/E) ratio of 3.82, implying the company greatly relies on financing operations through barrowing. Collegium Pharmaceutical has a current ratio of 0.97, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Collegium Pharmaceutical's use of debt, we should always consider it together with its cash and equity. | |
| Over 98.0% of Collegium Pharmaceutical shares are held by institutions such as insurance companies |
Collegium Pharmaceutical uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Collegium Pharmaceutical. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Collegium Pharmaceutical's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Follow Collegium Pharmaceutical's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 939.45 M.Project Collegium Pharmaceutical's profitablity
The company has Profit Margin (PM) of 0.15 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.35 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.35.When accessing Collegium Pharmaceutical's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Collegium Pharmaceutical's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Collegium Pharmaceutical's profitability and make more informed investment decisions.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Collegium Pharmaceutical insiders, such as employees or executives, is commonly permitted as long as it does not rely on Collegium Pharmaceutical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Collegium Pharmaceutical insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Collegium Pharmaceutical time-series forecasting models is one of many Collegium Pharmaceutical's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Collegium Pharmaceutical's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Collegium Pharmaceutical Earnings per Share Projection vs Actual
Collegium Pharmaceutical Corporate Management
| Shirley JD | General VP | Profile | |
| Bart Dunn | Executive Development | Profile | |
| Scott Sudduth | Head Operations | Profile | |
| Christopher MD | Vice Relations | Profile | |
| Marlo Manning | Head HR | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collegium Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. If investors know Collegium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collegium Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collegium Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Collegium Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collegium Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.